Shreeram Aradhye: Novartis Ianalumab Phase III Trial Meets Primary Endpoint in ITP
Shreeram Aradhye, President, Development and Chief Medical Officer at Novartis, shared an announcement on LinkedIn:
”Primary immune thrombocytopenia (ITP) is a rare autoimmune blood disorder characterized by low platelet counts leading to an increased risk of bleeding, bruising and chronic fatigue. For many people living with ITP, chronic treatment can disrupt their daily life due to the burden of regular dosing, dose adjustments and side effects.
Today, we announced positive top-line results from our investigational treatment in primary ITP.
This marks our second positive data readout for this investigational asset as yesterday we announced positive Phase III results in Sjögren’s disease – reinforcing our efforts to addressing areas of high unmet needs across B-cell driven diseases.
With over two decades of experience advancing care in ITP, this milestone underscores our commitment to continuing to innovate with the aim of finding new and meaningful ways to improve patient outcomes.
I would like to extend my gratitude to the patients, families, and teams who made this possible as we reimagine medicine together.”
Read more about Shreeram Aradhye’s announcement here.
Stay updated on the latest breakthroughs in drug development with Hemostasis Today.
-
Jul 2, 2026, 11:52Praveen Kumar Tirlangi: A New Mechanism of Bleeding in Kyasanur Forest Disease
-
Jul 2, 2026, 11:17Heghine Khachatryan: Novel Biomarkers for Cancer-Associated Thrombosis
-
Jul 2, 2026, 11:17Neeraj Jain: Maharashtra Is Setting the Pace for Integrated Hemoglobinopathy Care
-
Jul 2, 2026, 11:11Safaa Hilal: Improving Postpartum Hemorrhage Outcomes Through Early Warning Scores
-
Jul 2, 2026, 11:10Maria Khan Junaidi: How Age Influences Intracerebral Hemorrhage Outcomes
-
Jul 2, 2026, 10:51Faces of Glanzmann Thrombasthenia – Glanzmann’s Research Foundation
-
Jul 2, 2026, 10:44Priya Sriskandarajah: Understanding Anemia of Chronic Disease in Clinical Practice
-
Jul 2, 2026, 10:42Flora Peyvandi: Germline-Targeting Vaccines for HIV
-
Jul 2, 2026, 10:29Nisar Ahmed: The Evolution of Anticoagulation Therapy